Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... Lilly last week reported a rare $1.5 billion sales ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe ...
Wall Street Journal8d
Eli Lilly’s Bad Quarter Doesn’t Change Long-Term Math on Obesity Bonanza
Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad ...
STAT8d
Eli Lilly hits rare stumble, as sales and earnings disappoint
Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral ...